Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Sanofi Capital/Financing Update 2015

Nov 16, 2015

1643_rns_2015-11-16_33adf548-f103-4241-a715-75c4a449e3c6.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Final Terms dated 16 November 20L5

Issue of EUR 260,000,000 1.75 per cent. Notes due 10 September 2026 to be consolidated and form a single series with the existing EUR 1,250,000,000 1.75 per cent. Notes due 10 September 2026 under the Euro 15,000,000,000 Euro MedÍum Term Note Programme

PART ^4, - CONTRACTUAL TERMS

Terms used herein shall be deemed to be defined as such for the purposes of the Conditions (the "201.4 Conditions") set forth in the base prospectus dated 27 March 2014. This document constitutes the Final Terms of the Notes described herein for the purposes of Article 5.4 of the Prospectus Directive (as defined in the Base Prospectus dated 27 March 2015) and must be read in conjunction with the Base Prospectus dated 27 March 2015 and the Supplements to the Base Prospectus dated 26 May 2015, I September 2015 and l0 November 2015 which together constitute a base prospectus for the purposes of the Prospectus Directive (the "Base Prospectus"), save in respect of the 2014 Conditions which are extracted from the base prospectus dated 27 March 2014 and are incorporated by reference herein. For the avoidance of doubt, the Conditions contained in the Base Prospectus are not incorporated by reference herein. Full information on the Issuer and the offer ofthe Notes is only available on the basis of the combination of these Final Terms, the Base Prospectus and the 2014 Conditions. The Base Prospectus and the Final Terms are available for viewing at Sanofi, 54 rue La Boétie, 75008Paris, France during normal business hours and copies will also be available on the Luxembowg Stock Exchange website fuwwþøaeJù.

(
Ð
N
be
S
ies
um
r:
er		 19
(
ii
)
T
he
N
be
um
r:
ra
nc		 2
(ii
i
)
he
D
hi
ch
t
N
at
ot
o
n
e
b
w
es
ec
om
e
ib
le
tu
ng		 , f
in
gl
Th
No
sh
al
l b
ol
id
ed
rie
d
te
at
be
or
m
e
s
e
co
ns
a
s
e
se
s
an
f
i
th
h
t
o
r
ad
in
tr
in
ha
bl
w
e
E
te
pu
rp
os
es
g
o
rc
ng
ea
e
ur
l0
No
du
1,
25
0,
00
0,
00
0
1.
75
te
S
be
20
26
t.
te
p
er
e
c
en
s
ep
m
r
l
)
(t
he
19
(S
N
"
)
ie
T
he
"
E
xi
in
ot
st
hi
ch
es
er
s
ra
nc
g
, w
is
ol
id
io
t
bo
2
8
De
be
at
ed
ut
ct
or
o
oc
cu
r o
n
a
ce
m
r
co
ns
n
ex
pe
20
15
2 C
Sp
if,r
C
ies
ed
ur
re
nc
or
y
ur
re
nc
:
ec		 (
"E
U
R
"
)
Eu
ro
3 No
in
al
A
f N
Ag
nt
at
ot
m
m
ou
o
gr
eg
e
es
:
(
Ð
S
ies
er
:		 EU
R
1,
51
0,
00
0,
00
0
(
)
ii
T
he
ra
nc
:		 EU
R
26
0,
00
0,
00
0
4 Iss
P
ric
ue
e:		 f
f
th
N
in
al
A
nt
Ag
10
0.
93
1
pe
r
nt
. o
at
o
e
om
m
ou
ce
gr
eg
e
r 2
lu
of
Tr
ch
N
be
0.
32
99
18
th
Ag
p
er
t.
at
p
s
an
e
um
c
en
e
gr
eg
e

2r

Nominal Amount of Tranche Number 2 corresponding to the accrued interest for the period from, and including, 10 September 2015 to, but excluding, l8 November 2015.

5 (
)
D
i
i
t
e
n
o
m
n
a
o
n
s
:
Sp
ifie
d
ec		 EU
R
10
0,
00
0
6 (
Ð
D
t
a
e
:
I
ss
ue		 N
be
r 2
01
5
18
ov
em
D
(
)
t
ii
a
e
:
I
Co
nt
t
t
er
es
m
m
en
ce
m
en		 S
r 2
01
10
be
5
te
ep
m
7 D
t
a
e
:
M
ity
at
ur		 S
be
r 2
02
6
10
te
ep
m
8 B
i
a
s
s
:
In
te
st
re		 Fi
d
Ra
te
1.7
5
t.
pe
r c
xe
en
9 f
C
ha
o
In
te
st
o
r
R
ed
io
pt
ng
e
re
em
Pa
t
Ba
sis
ym
en
:		 n/
No
t A
lic
ab
le
pp
10 l O
i
t
p
o
n
s
:
Pu
t/C
al		 is
io
de
io
be
lo
w
el
in
pt
at
to
Se
pr
ov
ns
r
g
re
m
n
e
I l (
N
Ð
t
o
e
s
:
of
S
th
ta
tu
s
e		 U
ub
di
d
te
No
te
ns
or
na
s
f
(
ii
)
o
of
l f
B
rd
D
is
at
oa
a
pp
ro
va
or
e
su
an
ce
b
i
d
t
o
a
n
e
:
No
te
s		 4
d'
A
dm
in
is
tio
he
ld
C
tra
Fe
br
2
01
5
d
il
th
n
o
n
ua
ry
an
on
se
e
f M
O
D
ire
f t
liv
ie
Br
di
ct
G
én
ër
al
he
de
ci
si
t,
r
eu
r
r
an
co
ur
o
on
o
l0
N
be
Iss
da
d
r 2
01
5
te
ov
em
ue
r,
12 D
i
ri
b
i
t
t
s
u
o
n
:
. M
ho
d
of
et		 Sy
nd
ica
te
d
P
R		 (I
G
S
O
V
IS
IO
N
S
R
E
LA
T
IN
O
I
N
T
E
R
E
T
T		 F
A
N
Y
)
PA
Y
A
B
LE
13 P
i
i
ro
v
s
o
n
s
. F
ixe
d
Ra
N
te
ot
e
(C
di
tio
5(
a)
)
on
n		 A
lic
ab
le
pp
(
i
)
I
t
t
n
e
re
s
:
of
R
at
e		 eÍ
ab
le
al
ly
in
1.7
ft.
p
er
5
pe
r c
a
nn
un
p
ay
an
nu
a
rre
ar
D
(
)
t
(
ii
)
a
e
s
:
I
Pa
nt
t
t
er
es
ym
en		 r i
10
S
be
te
n
ch
ea
r
y
ep
m
ea
A
t
(ii
i
)
m
o
n
u
:
Fi
d
Co
xe
up
on		 N
in
al
r E
U
R
A
EU
R
in
nt
1,
75
0
10
0,
00
0
om
pe
m
ou
A
(
)
t
(iv
)
m
o
n
s
u
:
Br
ok
en		 No
t A
lic
ab
le
pp
F
i
t
(v
)
ra
c
o
n
:
Da
C
nt
y
ou		 l (
IC
M
A
)
l/A
A
ct
ct
ua
ua
D
t
(v
i
)
a
e
s
:
Fi
d
In
te
st
xe
re		 l0
r i
S
be
te
n
ch
ea
r
y
ep
m
ea
f
f
(v
ii
)P
ty
o
ib
le
lc
ul
io
o
r
at
ar
r
es
po
ns
ca
n
(
i
f
t
In
A
te
st
nt
n
o
re
m
o
u
s
th
e
C
al
la
tio
Ag
t):
cu
n
en		 No
t A
lic
ab
le
pp
14 P
i
i
ro
s
o
n
s
v
Fl
tin
Ra
N
te
ot
oa
g
e
(C
di
tio
5(
b)
)
on
n		 No
t A
lic
ab
le
pp
15 P
i
i
ro
v
s
o
n
s
C
. Z
No
te
er
o
ou
po
n		 t A
lic
ab
le
No
pp
O
IS
IO
S
R
E
LA
T
IN
G
O
IO
P
R
V
N
T
R
E
D
E
M
PT
N
16 l O
i
t
p
o
n
. C
al		 A
lic
ab
le
pp

(Condition 7(c))

(
Ð		 (C
al
l):
O
pt
io
l R
ed
io
Da
(s
)
pt
te
na
em
n		 A
d
f
in
cl
ud
in
10
bu
nd
J
20
26
t
t e
lu
di
ny
ro
m
g
ay
a
un
e
o
xc
ng
M
ity
at
th
D
at
ur
e
e
(
ii
)		 O
io
l
(s
A
pt
t
Re
de
io
na
pt
m
o
un
m
n
(C
al
l)
of
No
te
h
:
e
ac		 f
E
U
R
E
U
R
N
)
ot
o
1
00
,0
00
p
e
r
1
00
,0
00
e
S
ci
he
d
pe
De
in
io
at
no
m
n
(ii
i		 )
If
in
t:
de
ab
le
p
ar
re
em
(a
)
M
in
im
A
R
ed
io
nt
pt
um
em
n
m
ou
:		 No
t A
lic
ab
le
pp
(b
)
M
im
R
ed
io
A
nt
pt
ax
um
em
n
m
ou
:		 t A
lic
ab
le
No
pp
(iv )
rio
d:
No
tic
pe
e		 t i
C
di
tio
7(
c)
As
et
n
on
n
ou
s
17 P
ut
(C		 O
io
pt
n
di
tio
7(
d)
)
on
n		 No
t A
lic
ab
le
pp
18 . M
ak
(C		 ho
le
R
ed
io
pt
n
e-
w
em
di
tio
7(
e)
)
on
n		 A
lic
ab
le
pp
(
D		 f
b
to
b
tif
ie
d
o
P
tie
Is
y
ar
s
e
no
su
er
D
M
ak
ho
le
R
ed
io
at
pt
d
e-
w
e
em
n
an
(
i
f
M
ak
ho
le
A
R
ed
io
nt
pt
e-
w
em
n
m
ou
in
C
di
tio
6(
e)
):
he
ha
ot
r t
t o
ut
on
n
n
se		 in
C
As
di
tio
6(
e)
t
et
ou
on
n
s
(
ii
)		 M
gi
M
ak
ho
le
R
ed
io
pt
e-
w
ar
n
em
n		 eî
um
0.
15
t.
pe
r a
p
er
c
nn
(ii
i
)		 f
f
ba
si
D
is
tin
o
r
o
co
un
g
s
pu
rp
os
es
f
lc
ul
in
th
t v
at
al
o
pr
es
en
ca
g
su
m
e
ue
s
of
ai
ni
he
ts
t
ch
ed
ul
ed
r
em
ng
p
ay
m
en
s
rin
ci
l a
of
in
nd
te
st
Re
de
ed
p
pa
re
o
n
em
i
f
he
N
n
t
ot
d
in
io
o
et
at
he
es
t
er
m
n
M
ak
ho
le
A
R
ed
io
nt
pt
e-
m
ou
w
em
n
:		 A
l
nn
ua
(iv
)		 Se
rit
Re
fe
cu
re
nc
e
y:		 D
B
R
in
M
Bu
nd
at
Re
fe
1
t.
1
2
02
4
.5
pe
r c
m
ur
g
on
5
ay
en
re
nc
e
IS
IN
ith
D
E0
01
10
23
58
w
(v
)		 fe
Re
De
al
re
nc
e
er
s		 BN
P
Pa
rib
as
C
t A
ic
ol
In
t B
k
ré
di
Co
d
st
at
gr
e
ve
m
en
an
rp
or
e
an
G
B
k
A
, L
do
Br
ch
De
ut
he
an
on
n
an
sc
N
ix
is
at
(v
i
)		 Ag
t:
en
Q
tio
ta
uo
n		 BN
P
S
Se
Pa
rib
itie
ice
as
ec
ur
s
rv
s
19 . E
a
re
as
(C
on		 rl
A
t
(ta
tio
R
ed
io
y
pt
m
o
un
n
em
n
xa
s)
on
di
tio
7(
b)
(Ð
)
nd
7
n
a		 E
rl
(s
)
p
e
r
C
R
ed
io
A
al
la
tio
pt
nt
A
a
y
nt
m
ou
cu
n
em
n
m
ou
fd
ef
fo
lt
bl
ed
io
pt
r t
nt
o
au
pa
ya
e
r
em
n
ax
r
ea
so
ns
on
, o
n
an
e
ve
(o
th
he
rl
ha
ot
de
io
t
o
r
pt
M
ak
ho
le
er
a
ny
r
ea
n
y
re
m
n
e-
w
he
d/
r t
of
)
de
io
bo
ho
d
pt
de
rib
ed
et
a
s
a
ve
an
o
m
re
m
n
sc
if
(if
d
iff
fro
th
ui
d
t
ha
lc
ul
in
t
t s
at
e
r
eq
re
or
er
en
m
et
ca
g
sa
m
e
C
):
t i
di
tio
th
n
on
ns
ou
e
f
E
U
R
E
U
R
N
ot
o
p
e
r
1
00
,0
00
1
00
,0
00
e
S
cif
ie
d
pe
De
in
io
at
no
m
n
G
E
N
E
R
A
L
O
IS
IO
S
A
P
P
LI
C
A
B
LE
T
O
T
H
E
N
O
T
ES
P
R
V
N
20. Form of Notes:
  1. Form ofNotes Dematerialised Notes

r

(
Ð
f D
F
ia
lis
ed
No
at
te
or
m
o
em
er
s:		 )
te
f
(
Be
d
ia
lis
ed
p
or
ur
at
au
or
m
ar
er
em
er
(
ii
)
R
ist
tio
Ag
t:
eg
ra
n
en		 No
t A
lic
ab
le
pp
(ii
i
)
Te
G
lo
ba
l C
tif
i c
at
m
po
ra
ry
er
e:		 No
t A
lic
ab
le
pp
2
1.		 A
dd
iti
al
F
in
ci
al
C
(s
)
o
r
tre
he
ot
on
an
en
r
t
vi
si
la
tin
ia
l p
o
P
ro
on
s
re
g
t
sp
ec
ay
m
en
Bu
si
D
ne
ss
ay
s:		 No
t A
lic
ab
le
pp
22 fo
ch
ed
fu
C
b
at
ta
. T
al
tu
to
r
e
on
s
re
ou
po
ns
to
D
ef
in
iti
(
d
N
ot
da
hi
ch
an
te
on
ve
es
s
w
T
al
e)
at
ch
on
s
m
ur
:
su		 N
o
23 d
. R
ed
in
io
in
al
is
io
at
at
a
n
en
om
n,
r
en
om
n
vi
si
tio
ni
p
ro
on
s:
re
co
nv
en
ng		 N
A
lic
ab
le
ot
pp
24 is
io
. C
lid
io
at
pr
ov
ns
on
so
n
:		 No
t A
lic
ab
le
pp
25 of
f N
Re
tio
h
ol
de
ta
ot
o
pr
es
en
n
rs
es
:		 C
di
tio
lie
13
on
n
a
pp
s
In
iti
al
R
ive
ha
ll
be
Th
nt
at
ep
re
se
s
:
e
C
hr
ist
ia
Ho
ch
st
n
ra
ss
er
G
G
én
ér
al
lle
2
du
de
au
ru
e
G
Co
la
nd
vi
lle
54
87
0
ra
ns
Fr
ce
an
A
lte
iv
Th
at
Re
tiv
sh
al
l b
ta
m
e
e
pr
es
en
e
e:
Sa
d'
Ha
nd
rin
us
sy
e
G
69
be
tta
ru
e
am
00
S
ai
-M
r-d
-F
sé
nt
94
I
au
es
os
s
Fr
an
ce
ill
of
tit
le
d
to
io
E
U
R
Th
Re
tiv
b
at
ta
w
en
re
m
un
er
n
e
pr
es
en
e
e
a
45
0
pe
r y
ea
r.
IS
D		 IO
T
R
IB
U
T
N
26 (
i
)
f
I
f
o
nd
nd
ica
d,
te
dd
sy
n
am
es
a
a
re
ss
es
d
M
a
n
de
rit
in
a
n
a
g
e
rs
un
rw
g
i
t
t
c
o
m
m
m
e
n
s
:		 B
A
N
K
, B
E
LG
IA
N
B
RA
N
C
H
IN
G
N
V
M
ix
24
Av
am
en
ue
10
00
B
el
ru
ss
s
m
Be
lg
iu
EU
R
13
0,
00
0,
00
0
C
M
O
R
G
A
N
S
EC
S
PL
U
R
IT
IE
J.
P.
B
k
St
25
et
an
re
W
ha
rf
Ca
na
ry
Lo
nd
E
14
5
JP
on
m
Ki
do
U
ni
d
te
ng
EU
R
13
0,
00
0,
00
0
(
ii
)
of
S
D
ub
rip
tio
Ag
at
t:
e
sc
n
re
em
en		 l6
N
be
r 2
01
5
ov
em
27 I
f
of
d
di
d,
ad
dr
te
na
m
e
an
n
on
-s
yn
ca
es
s		 t A
lic
ab
le
No
pp

?r

Dealer:

  1. US Selling Restrictions:

Reg. S Compliance Category 2; TEFRA not applicable

  1. Non-exempt Offer:

Not Applicable.

By: Signed on behalfofthe Issuer:

Duly authorised

Olivier KLARIC Vice-President Financing and Treasury SANOFI

PART B - OTHER INFORMATION

1. ADMISSION TO TRÄDING AND LISTING

(
Ð
A
dm
iss
io
ad
in
lis
tin
tr
d
to
g:
n
g
an		 (o
fo
its
A
lic
at
io
by
th
Iss
b
eh
al
f)
ha
be
ad
r o
r
pp
n
e
ue
r
s
en
m
e
n
t
di
t
be
li
ed
th
No
to
b
ad
itt
ed
tra
nd
st
te
th
o
o
e
ng
a
o
n
e
s
m
e
ith
L
is
of
Ex
ch
O
ffr
ci
al
t
he
L
bo
St
k
ffe
t
ct
w
ux
em
ur
g
oc
an
ge
e
fro
No
be
r 2
01
5.
1
8
m
ve
m
ad
itt
ed
t
li
ed
Th
Ex
ist
in
No
te
al
ad
tra
di
nd
st
m
o
e
g
s
ar
e
re
ng
a
y
fth
O
ffi
ci
al
L
is
Lu
bo
St
k
t o
Ex
ch
th
e
xe
m
ur
g
oc
an
ge
on
e
(
)
i
i
of
l e
E
im
to
ta
lat
ed
st
at
e
re
xp
en
se
s
dm
iss
io
ad
in
to
to
tr
g:
a
n		 EU
R
93
5
R
A
T
IN
G
S
Ra
tin
gs
:		 No
b
iss
d
d:
Th
te
to
te
s
e
ue
ra
e
ar
e

Standard & Poor's Credit Market Services Europe Limited ("S&P"): AA

Moody's France S.A.S. ("Moodyrs"): Al

S&P and Moody's are established in the European Union and registered under Regulation (EC) No 1060/2009 (the "CRA Regulation"), as amended. As such S&P and Moody's are included in the list ofcredit rating agencies published by the European Securities and Markets Authority on its website (http ://www. esma. europa.er¡/pase/List-registered-andcertified-CRAs) in accordance with the CRA Regulation.

3. INTERESTS OF NATURÄL AND LEGAL PERSONS INVOLVED IN THE ISSUE

So far as the Issuer is aware, no person involved in the offer of the Notes has an interest material to the offer.

4. REASONS FOR THE OFFER

The net proceeds ofthe issue ofthe Notes will be used for the general corporate purposes ofthe Issuer

FÍxed Rate Notes only- YIELD 5

Indication ofyield: 1.655 per ceît. per annum

FloatÍng Rate Notes only - HISTORIC INTEREST RATES 6

Not Applicable.

TERMS AND CONDITIONS OF THE OFT'ER 7

Not Applicable

2

,r

8. PLACING AND UNDERWRITING

Not Applicable

9 OPERATIONAL INFOR}IATION

(Ð ISIN Code: (ii) Common Code: Until the Notes are consolidated and form a single Series with the Existing Notes, the Notes will have the temporary ISIN FR0013054046. After that, the Notes will have the same ISIN as the Existing Notes, which is FR00l2l4680l Until the Notes are consolidated and form a single Series with the Existing Notes, the Notes will have the temporary Common Code 132188017. After that, the Notes will have the same Common Code as the Existing Notes, which is tt0774346

(iii) Depositaries:

  • (a) Euroclear France to act as Yes Central Depositary:
  • (b) Common Depositary for No Euroclear Bank and Clearstream Banking, sociétë anonymei
  • (iv) Any clearing system(s) other than Euroclear France, Euroclear Bank SA/NV and Clearstream Banking société anonyme and the relevant identification number(s) : Not Applicable

(v) Delivery: (vi) Names and addresses of initial Paying Agents: Delivery against payment BNP Paribas Securities Services (affiliated with Euroclear France under number 29106) 9, rue Débarcadère 93761 Pantin cedex France

(vii)Names and addresses of additional Paying Agent(s) (if any): Not Applicable

-7 - 189645-4-l -v0.9 3640614721

More from Sanofi

Regulatory Filings 2026
May 19
Regulatory Filings 2026
May 19
Regulatory Filings 2026
May 18
Regulatory Filings 2026
May 18
Regulatory Filings 2026
May 5
Transaction in Own Shares 2026
Apr 29
Transaction in Own Shares 2026
Apr 29
Declaration of Voting Results & Voting Rights Announcements 2026
Apr 29
Declaration of Voting Results & Voting Rights Announcements 2026
Apr 29
Regulatory Filings 2026
Apr 29
View all filings →